Mark E. Morrison
Impact in
- Oncology top 5%
- Lung Cancer Research Studies
- Peptidase Inhibition and Analysis
- Epidemiology top 10%
- Neuroendocrine Tumor Research Advances
Papers in
- Oncology 3
- Peptidase Inhibition and Analysis 2
- Lung Cancer Research Studies 1
- Co-authors
- Benjamin Wang (1 shared paper)Corey J. Langer (1 shared paper)Nasser H. Hanna (1 shared paper)Thaddeus Beck (1 shared paper)Rafat Ansari (1 shared paper)Paul A. Bunn (1 shared paper)Peter Ellis (1 shared paper)Lawrence H. Einhorn (1 shared paper)
- Journals
- Journal of Clinical Oncology (2 papers)Proceedings of the National Academy of Sciences (1 paper)Genomics (1 paper)Biochemistry (1 paper)The Journal of Experimental Medicine (1 paper)
- Partner nations
- United States
In The Last Decade
Mark E. Morrison
6 papers receiving 751 citations
Mark E. Morrison's Hit Papers
Peers
Comparison fields: 5 of 56
- Oncology 626
- Epidemiology 237
- Physiology 22
- Cellular and Molecular Neuroscience 78
- Pulmonary and Respiratory Medicine 96
Countries citing papers authored by Mark E. Morrison
This map shows the geographic impact of Mark E. Morrison's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Mark E. Morrison with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Mark E. Morrison more than expected).
Fields of papers citing papers by Mark E. Morrison
This network shows the impact of papers produced by Mark E. Morrison. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Mark E. Morrison. The network helps show where Mark E. Morrison may publish in the future.
Co-authors
The 25 scholars most cited alongside Mark E. Morrison, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.
All Works
| # | Work | ||
|---|---|---|---|
| 1 | Randomized Phase III Trial Comparing Irinotecan/Cisplatin With Etoposide/Cisplatin in Patients With Previously Untreated Extensive-Stage Disease Small-Cell Lung Cancer Hit paper breakdown → | 2006 | 526 |
| 2 | 1993 | 151 | |
| 3 | 2006 | 53 | |
| 4 | 1985 | 37 | |
| 5 | 1983 | 14 | |
| 6 | 1994 | 7 |
About Mark E. Morrison
Mark E. Morrison is a scholar working on Oncology, Molecular Biology, Cell Biology, Organic Chemistry and Pharmacology, having authored 6 papers that have together received 788 indexed citations. Recurring topics across this work include Peptidase Inhibition and Analysis (2 papers), melanin and skin pigmentation (2 papers), Cell Adhesion Molecules Research (1 paper), Lung Cancer Research Studies (1 paper), Computational Drug Discovery Methods (1 paper), Free Radicals and Antioxidants (1 paper), Inflammatory mediators and NSAID effects (1 paper) and Neuroendocrine Tumor Research Advances (1 paper). The work is most often cited by research in Oncology (626 citations), Epidemiology (237 citations), Physiology (22 citations), Cellular and Molecular Neuroscience (78 citations) and Pulmonary and Respiratory Medicine (96 citations). Mark E. Morrison has collaborated with scholars based in United States. Frequent co-authors include Benjamin Wang, Corey J. Langer, Nasser H. Hanna, Thaddeus Beck, Rafat Ansari, Paul A. Bunn, Peter Ellis, Lawrence H. Einhorn, Michael Byrne and Alan Sandler. Their work appears in journals such as Journal of Clinical Oncology, Proceedings of the National Academy of Sciences, Genomics, Biochemistry and The Journal of Experimental Medicine.
Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.